Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2117)	1/14/2008 10:11:00 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CGEN has been up 10% on moderate volume.(It is still up 8% <g>) bigcharts.marketwatch.com It announced today a collaboration with MRK, targeted at predicting peptides likely to activate selected GPCRs & validating their agonistic activity. The agreement includes an option to MRK for exclusive worldwide licenses on a peptide by peptide basis,covering the development of therapeutic products. CGEN also has an agreement with TEVA to discover biomarkers that can indicate drug toxicity prior to clinical stages of drug development, CGEN needs to close above $2.50 in order to get off from the DT coming from its July H at $3.16 bigcharts.marketwatch.com Bernard